Clinical Trials To Begin For Sona Nanotech’s COVID-19 Rapid Saliva Test

Sona Nanotech Inc. (CSE: SONA) announced after market close last night that it has received the go signal from the research ethics board to proceed with the previously approved clinical trials for its saliva-based COVID-19 rapid antigen test. The trials are expected to begin next week.

The clinical trials will seek to test up to 500 emergency room patients suspected of having COVID-19 in Humber River Hospital in Toronto. This process, which is expected to last four to ten weeks, seeks to determine the clinical performance of the saliva test in comparison to RT-PCR among symptomatic patients.

Should the trials yield successful results, additional analytical validation studies from third-party agencies would be commissioned to support any future regulatory submissions.

Sona Nanotech Inc. last traded at $1.82 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Uranium Is Back On America’s Radar | Corey Dias –  Anfield Energy

The Russell Will Lead the Next Market Crash!? | John Feneck

The Global Conflict Has Already Started | Bryan Cunningham

Recommended

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Altamira Gold Encounters Porphyritic Intrusive Rocks In Initial Scout Drilling At Regional Targets

Related News

Sona Nanotech Releases News.. About Planning To Release News

A tumbling share price can make companies do odd things. If you’re Sona Nanotech (CSE:...

Thursday, August 20, 2020, 10:15:59 AM

Sona Nanotech Withdraws Health Canada Application For COVID-19 Test Due To Feedback From Regulator

In what is a major blow to shareholders of Sona Nanotech (CSE: SONA), the company...

Wednesday, November 25, 2020, 02:31:06 PM

Sona Nanotech’s Rapid Antigen Test Approved For Sale In Europe Via CE Mark Approval

Sona Nanotech (CSE: SONA) has been granted CE Mark status for its rapid COVID-19 antigen...

Thursday, December 31, 2020, 09:33:17 AM

Sona Nanotech Announces $2.0 Million Private Placement

Sona Nanotech (CSE: SONA) this morning announced that it is looking to raise funds via...

Thursday, December 3, 2020, 09:27:21 AM

Sona Nanotech Approved For Clinical Trials of Saliva-Based COVID-19 Rapid Test

Sona Nanotech (CSE: SONA) has been approved to begin clinical trials. The company this morning...

Tuesday, April 13, 2021, 08:21:40 AM